To see all protocols that comply with the WHO Essential Medicine List 
  1. Home
  2. Haematology and BMT
  3. Lymphoma
  4. Non-Hodgkin lymphoma

Pembrolizumab (flat dosing)

Treatment must be initiated and supervised by specialist physicians experienced in the treatment of cancer using immunological agents. Before commencing immunotherapy treatment in any patient, clinicians should have an understanding of the immune-related adverse events (irAEs) associated with immunotherapy treatment and their management.

Patients with lymphoma should be considered for inclusion into clinical trials. Link to ALLG website, ANZCTR website and Lymphoma Australia website.

This protocol is based on limited evidence; refer to the evidence section of this protocol for more information.

On this page
Expand all Collapse all Back to top

Cycle 1 and further cycles

Drug Dose Route Day
Pembrolizumab 200 mg IV infusion 1
Frequency:
21 days 
Cycles:
35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment)
Notes:

In the first few months after the start of immunotherapy, some patients can have a transient tumour flare (termed 'pseudo progression' or an immune response). This may manifest as growth of existing lesions or the development of new lesions prior to later tumour regression. While this is rare, (~5%), continuing treatment and performing a second scan 4 to 6 weeks later to confirm progression may be considered, particularly if the patient is believed to be deriving clinical benefit.

Radiation recall has been observed with PD1 inhibitors, consideration should be given to the timing when starting this treatment after a prolonged course of radiation therapy.

Drug status:

Pembrolizumab: (PBS authority)

Cost:
~ $8,290 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes antineoplastic drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au), MIMS Online and other sources. These costs are reviewed and updated on eviQ at 6 monthly intervals.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on a 28 day month.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses and ongoing maintenance doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Cycle 1 and further cycles

Day 1
Pembrolizumab 200 mg (IV infusion) in 50 mL sodium chloride 0.9% over 30 minutes
Frequency:
21 days 
Cycles:
35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment)

Cycle 1 and further cycles

Drug Dose Route Day
Pembrolizumab 200 mg IV infusion 1
Frequency:
21 days 
Cycles:
35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment)
Notes:

In the first few months after the start of immunotherapy, some patients can have a transient tumour flare (termed 'pseudo progression' or an immune response). This may manifest as growth of existing lesions or the development of new lesions prior to later tumour regression. While this is rare, (~5%), continuing treatment and performing a second scan 4 to 6 weeks later to confirm progression may be considered, particularly if the patient is believed to be deriving clinical benefit.

Radiation recall has been observed with PD1 inhibitors, consideration should be given to the timing when starting this treatment after a prolonged course of radiation therapy.

Drug status:

Pembrolizumab: (PBS authority)

Cost:
~ $8,290 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes antineoplastic drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au), MIMS Online and other sources. These costs are reviewed and updated on eviQ at 6 monthly intervals.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on a 28 day month.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses and ongoing maintenance doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Cycle 1 and further cycles

Day 1
Pembrolizumab 200 mg (IV infusion) in 50 mL sodium chloride 0.9% over 30 minutes
Frequency:
21 days 
Cycles:
35 or until disease progression or unacceptable toxicity (total maximum of 35 doses or 24 months treatment)

Indications:

  • Monotherapy for relapsed or refractory classical Hodgkin lymphoma
    • following autologous stem cell transplant (ASCT) OR 
    • following at least two prior therapies when ASCT is not a treatment option 

Precautions: 

If any of these conditions are present, clinical judgement should be used and individual cases discussed with an expert in the field as indicated:

  • significant autoimmune disease (e.g. myasthenia gravis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, autoimmune ocular disease)
  • organ transplantation
  • previous history of viral hepatitis
  • HIV/acquired immune deficiency syndrome (AIDS).

Indications:

  • Refractory primary mediastinal large B-cell lymphoma, or who have relapsed after 2 or more prior lines of therapy

Precautions: 

If any of these conditions are present, clinical judgement should be used and individual cases discussed with an expert in the field as indicated:

  • significant autoimmune disease (e.g. myasthenia gravis, inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, autoimmune ocular disease)
  • organ transplantation
  • previous history of viral hepatitis
  • HIV/acquired immune deficiency syndrome (AIDS).
Venous access required

IV cannula (IVC) or central venous access device (CVAD) is required to administer this treatment.

Read more about central venous access device line selection
Emetogenicity MINIMAL

No antiemetics should be routinely administered before treatment in patients without a history of nausea and vomiting. If patients experience nausea and/or vomiting, consider using the low antiemetic prophylaxis regimen.

Read more about preventing antineoplastic induced nausea and vomiting
Complications of allogeneic HSCT

Patients who received allogeneic haematopoietic stem cell transplant (HSCT) following discontinuation of pembrolizumab therapy experienced immune-mediated complications (some fatal) including graft versus host disease (GVHD) and severe sinusoidal obstructive syndrome (SOS; formerly called veno-occlusive disease) following reduced-intensity conditioning.

 Monitor closely for early signs/symptoms of transplant-related complications (e.g. hyper-acute GVHD, steroid-requiring febrile syndrome, SOS, and other immune-mediated adverse reactions) and manage promptly. 
Immune-related adverse events (irAEs)

Immune-related adverse events (irAEs) can occur early and escalate quickly in patients receiving immune checkpoint inhibitors. irAEs can also occur after discontinuation of treatment. Fatalities have been reported. 

Examples of irAEs include arthritis, colitis, endocrinopathies, Guillain-Barré syndrome, haemolytic anaemia, hepatitis, hypophysitis, myositis, nephritis, nerve paresis, autoimmune neuropathy, pancreatitis, rash, pneumonitis, uveitis, vasculitis. 

irAEs that carry a high risk of mortality include myocarditis, encephalitis, pneumonitis and hepatitis.

Proactive monitoring, patient self-monitoring and early reporting of adverse events is critical. Treatment interruptions and administration of corticosteroids and/or supportive care is required to minimise the risk of death.

See individual irAEs listed below for more information. 

Read more about the management of immune-related adverse events (irAEs)
Cardiac toxicity

Cardiac toxicities have been reported in patients receiving immune checkpoint inhibitor therapy. Although rare, myocarditis, pericarditis, arrhythmias, impaired ventricular function with heart failure and vasculitis and venous thromboembolism can occur. Myocarditis is rare but is associated with high mortality and should be excluded in any patient with cardiovascular symptoms particularly within the first three months of initiating immune checkpoint inhibitors.

Monitor patients for signs and symptoms of cardiac toxicity and refer to cardiologist if suspected.

Read more about the management of immune-related adverse events (irAEs)
Diabetes

Type 1 diabetes mellitus, including diabetic ketoacidosis, has been reported in patients receiving immune checkpoint inhibitor therapy.

Monitor patients for hyperglycaemia or other signs and symptoms of diabetes. Exclude other causes of diabetes.

Initiate insulin replacement as needed. Monitor blood sugar levels to ensure appropriate insulin replacement is achieved.

Read more about the management of immune-related adverse events (irAEs)
Gastrointestinal toxicity

Immune-related diarrhoea and colitis have been observed in patients receiving immune checkpoint inhibitor therapy, in some cases these adverse events have been severe.

Patients should be monitored for symptoms of increased frequency of bowel movements, change in the consistency of the stool, diarrhoea, abdominal pain, mucus in stools, haematochezia, and constitutional symptoms (fever, fatigue, weight loss). Exclude other causes of diarrhoea or colitis.

Clinical signs of peritonism should be immediately acted upon given the risk of bowel perforation.

Read more about the management of immune-related adverse events (irAEs)
Haematological toxicity

Haematological toxicities have been reported in patients receiving immune checkpoint inhibitor therapy. Although rare, autoimmune haematolytic anaemia (AIHA), acquired thrombotic thrombocytopenic purpura (TTP), aplastic anaemia (AA), immune thrombocytopenia (ITP), acquired haemophilia (AH), haemolytic uremic syndrome (HUS) and lymphopenia can occur.

Monitor patients for signs and symptoms of haematological toxicity and refer to haematologist if suspected.

Read more about the management of immune-related adverse events (irAEs)
Hepatotoxicity

Immune-related hepatitis has been observed in patients receiving immune checkpoint inhibitor therapy.

Monitor patients for signs and symptoms of hepatitis (e.g. abnormal LFTs, jaundice, dark urine, severe nausea and vomiting, pain on the right side of the abdomen) and exclude other causes.

Read more about the management of immune-related adverse events (irAEs)
Hypophysitis

Immune-related hypophysitis has been observed in patients receiving immune checkpoint inhibitor therapy.

Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and secondary adrenal insufficiency) and exclude other causes of hypophysitis.

Read more about the management of immune-related adverse events (irAEs)
Musculoskeletal toxicity

Musculoskeletal toxicities have been reported in patients receiving immune checkpoint inhibitor therapy. Although rare, inflammatory arthritis, polymyalgia-like syndrome and myositis can occur. 

Monitor patients for symptoms of musculoskeletal toxicities. Mild symptoms may be managed with analgesia such as paracetamol or non-steroidal anti-inflammatories (if not contraindicated). Moderate to severe symptoms may require corticosteroid therapy. Consultation with a rheumatologist is advised. For myositis, consultation with a neurologist is also advised.

Read more about the management of immune-related adverse events (irAEs)
Neurological toxicity

Rare but serious immune-related neurological events including neuropathies, encephalitis, aseptic meningitis, meningeal symptoms, Guillain-Barre syndrome and myasthenia gravis-like symptoms have been observed in patients receiving immune checkpoint inhibitor therapy.

Monitor for signs and symptoms of motor or sensory neuropathies and muscle weakness.

Read more about the management of immune-related adverse events (irAEs)
Ocular toxicity

Ocular toxicities have been reported in patients receiving immune checkpoint inhibitor therapy. Although rare, uveitis/iritis, episcleritis and blepharitis can occur. 

Monitor patients for signs and symptoms of ocular toxicity and refer to ophthalmologist if suspected.

Read more about the management of immune-related adverse events (irAEs)
Pulmonary toxicity

Immune-related pneumonitis has been observed in patients receiving immune checkpoint inhibitor therapy.

Monitor patients for signs and symptoms of pneumonitis (e.g. new or worsening cough, shortness of breath, or chest pain). If pneumonitis is suspected, evaluate with radiographic imaging (e.g. High Resolution CT) and exclude other causes of pneumonitis.

Read more about the management of immune-related adverse events (irAEs)
Renal toxicity

Immune-related nephritis and renal dysfunction have been observed in patients receiving immune checkpoint inhibitor therapy, in some cases the adverse events have been severe.

Monitor patients for changes in renal function (e.g. elevated serum creatinine, haematuria, decrease in urine output) and exclude other causes of nephritis.

Read more about the management of immune-related adverse events (irAEs)
Skin toxicity

Immune-related skin rash has been observed in patients receiving immune checkpoint inhibitor therapy.

Monitor for rash, erythema and pruritus (unless an alternate aetiology has been identified).

Read more about the management of immune-related adverse events (irAEs)

Link to ESMO schematic of body surface area
Thyroid toxicity

Immune-related thyroid disorders are common (hypothyroidism and hyperthyroidism) and can occur at any time during immune checkpoint inhibitor therapy.

Monitor patients for changes in thyroid function and clinical signs and symptoms of thyroid disorders.

Isolated hypothyroidism may be managed with replacement therapy, without treatment interruption, and without corticosteroids.

Read more about the management of immune-related adverse events (irAEs)
Blood tests

FBC, EUC, LFTs, serum cortisol, TFTs and BSL at baseline.

Repeat FBC, EUC, LFTs and BSL prior to each cycle and serum cortisol and TFTs alternate cycles. Check lipase and amylase if symptomatic of pancreatitis.

In the absence of suspicion of immune related adverse events less frequent monitoring may be applicable, according to institutional guidelines. Evidence for the frequency of routine blood testing with immunotherapies varies within published studies and guidelines.

Read more about immunotherapy blood test monitoring recommendations
Hepatitis and HIV

Hepatitis screening is recommended in all patients who are to receive immune checkpoint inhibitors, however the value of hepatitis and HIV screening is unknown and many trials no longer require screening prior to commencing immune checkpoint inhibitors.

Immunotherapy is associated with inflammatory adverse reactions resulting from increased or excessive immune activity and patients are at risk of developing autoimmune hepatitis. It should be used with caution in patients who have a history of chronic hepatic infections (hepatitis B and C) and human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).
Vaccinations

The safety of having vaccinations during treatment is unknown. Patients in the clinical trial were allowed to receive inactivated vaccines (e.g. inactivated influenza vaccine) but live vaccines (e.g. BCG, MMR, zoster and varicella vaccines) were typically not permitted.

Caution: in patients receiving combination ipilimumab and nivolumab there have been reported cases of fatal myocarditis, myositis and rhabdomyolysis shortly after administration of the influenza vaccine.  Whilst a causative relationship to the use of influenza vaccine has not been demonstrated, caution is advised.
Effects of cancer treatment on fertility

Cancer treatment can have harmful effects on fertility and this should be discussed with all patients of reproductive age prior to commencing treatment.

Studies to evaluate the effects of immune checkpoint inhibitor therapy on fertility have not been performed. Therefore, the effect on male and female fertility is unknown, however, immune checkpoint inhibitors can cause fetal harm when given to pregnant women. It is important that females of reproductive potential and males use effective contraception whilst on therapy and for at least 4 months post last dose of therapy.

Read more about the effect of cancer treatment on fertility
Evidence for dose modifications is limited, and the recommendations made on eviQ are intended as a guide only. They are generally conservative with an emphasis on safety. Any dose modification should be based on clinical judgement, and the individual patient’s situation including but not limited to treatment intent (curative vs palliative), the antineoplastic regimen (single versus combination therapy versus chemotherapy versus immunotherapy), biology of the cancer (site, size, mutations, metastases), other treatment related side effects, additional co-morbidities, performance status and patient preferences. Suggested dose modifications are based on clinical trial findings, product information and reference committee consensus. Non-haematological gradings are based on Common Terminology Criteria for Adverse Events (CTCAE) unless otherwise specified. Renal and hepatic dose modifications have been standardised where possible. For more information see dosing considerations & disclaimer.
  • dose reduction is not recommended
  • no dose adjustment is required in the elderly, mild or moderate renal impairment or mild hepatic impairment. Pembrolizumab has not been studied in patients with severe renal impairment or moderate to severe hepatic impairment.

Management of immune-related adverse events (irAEs)

Link to Management of immune-related adverse events (irAEs)

References & Disclaimer

Pembrolizumab
No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab. Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected.
  Interaction Clinical management
Immunosuppressants (inc. corticosteroids) Reduced efficacy of both immunosuppressants and pembrolizumab possible due to pharmacodynamic interaction

It is recommended that patients requiring corticosteroids prior to treatment receive the lowest possible dose (preferably no greater than 10 mg prednisolone or equivalent steroid per day). Once started on pembrolizumab the use of corticosteroids to treat immune related adverse events (irAEs) does not appear to impact the clinical response to pembrolizumab. In patients requiring ongoing corticosteroids post management of an irAE, the dose should be as low as possible.

Monitor for signs of organ rejection in transplant recipients.

Day 1

Approximate treatment time: 60 minutes

Immunotherapy patient assessment prior to each treatment.

Any toxicity may require delay of treatment and review by medical officer before commencing treatment.

Prime IV line(s).

Insert IV cannula or access port or CVC.

Pre treatment medication

Administer antiemetics if required

Pembrolizumab

Administer pembrolizumab:
  • a low protein binding 0.2 micron or 5 micron in-line or add-on filter should be used
  • via IV infusion over 30 minutes
  • observe for infusion-related reactions
  • flush with 50 mL of sodium chloride 0.9%.
Mild or moderate infusion-related reaction:
  • decrease the rate of infusion and monitor closely 
  • give any further doses with close monitoring
  • premedication with paracetamol and an antihistamine should be considered for further doses.
Severe infusion reaction:
  • stop infusion immediately 
  • medical officer review
  • permanently discontinue pembrolizumab.

Remove IV cannula and/or deaccess port or CVC.

Discharge Information

Patient information
  • Ensure patient receives patient information sheet.

The side effects listed below are not a complete list of all possible side effects for this treatment. Side effects are categorised into the approximate onset of presentation and should only be used as a guide.

The most common side effects with this treatment are immune-related adverse events (irAEs). irAEs can escalate quickly and close monitoring of the patient is required. Symptoms should improve promptly after the introduction of immunosuppressive therapy. If this does not occur review the diagnosis and seek further specialist advice. Refer to the Management of immune related adverse events document for further information.

Immune related adverse events
Cardiotoxicity

Cardiotoxicity is a rare but serious side effect, which may manifest as asymptomatic reduction in left ventricular ejection fraction (LVEF), arrhythmia, cardiomyopathy, myocarditis, pericarditis, cardiac fibrosis, hypertension, cardiac ischaemia, congestive heart failure (CHF) and cardiac arrest.

Read more about Management of immune related adverse events.
Gastrointestinal toxicity

Colitis, diarrhoea or more bowel movements than usual; blood or mucous in stools; dark, tarry, sticky stools; abdominal pain or tenderness.

Read more about Management of immune related adverse events
Haematological toxicity

Autoimmune haemolytic anaemia (AIHA), acquired thrombotic thrombocytopenic purpura (TTP), aplastic anaemia (AA), immune thrombocytopenia (ITP), acquired haemophilia (AH), haemolytic uremic syndrome (HUS) and lymphopenia are rare but potentially serious immune-related adverse events associated with immunotherapy treatment.

Read more about Management of immune related adverse events.
Hepatotoxicity

Transaminase and total bilirubin elevation, jaundice, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark urine, bleeding or bruising more easily than normal, anorexia.

Read more about Management of immune related adverse events.
Musculoskeletal toxicity

Inflammatory arthritis, temporal arteritis, arthralgia, myalgia, synovitis, vasculitis, polymyalgia-like syndrome and myositis.

Read more about Management of immune related adverse events.
Neurological toxicity

Aseptic meningitis, myasthenia gravis, Guillain-Barre syndrome, encephalitis, meningeal symptoms, neuropathy and acute inflammatory demyelinating polyneuropathy are infrequent but potentially serious immune-related adverse events associated with immunotherapy treatment.

Read more about Management of immune related adverse events.
Ocular toxicity

Eye pain, blurred vision, Uveitis/iritis, episcleritis,  blepharitis, optic neuritis, tear duct stenosis, conjunctivitis, hyperlacrimation, watery or dry eyes and photophobia. 

Read more about Management of immune related adverse events.
Other endocrinopathies

Type 1 diabetes mellitus, hypophysitis, hypopituitarism and adrenal insufficiency are infrequent but potentially serious immune-related adverse events associated with immunotherapy treatment.

Read more about Management of immune related adverse events
Pulmonary toxicity

Radiographic changes, dyspnoea, new or worsening cough, hypoxia, tachycardia, chest pain or fever.

Read more about Management of immune related adverse events.
Renal toxicity

Increase in serum creatinine, oliguria, haematuria, peripheral oedema and anorexia.

Read more about Management of immune related adverse events.
Skin toxicity

Rash including full thickness, pruritus, skin blisters, ulceration and necrosis. Radiation recall can occur at site of previous radiotherapy. Symptoms include vesiculation, desquamation and ulceration of the skin.

Read more about Management of immune related adverse events
Thyroid toxicity

Thyroid toxicity is common with immune checkpoint inhibitors. Hypothyroidism is most frequent however hyperthyroidism can also occur.

Read more about Management of immune related adverse events

Non-immune related adverse events
Fatigue

Read more about fatigue

The rationale for pembrolizumab, a humanised IgG4/k monoAb that blocks binding between PD-1 & its ligands, is due to the fact that malignant Reed-Sternberg cells in classical Hodgkin lymphoma frequently have 9p24.1 alterations, resulting in over-expression of PD-L1 and PD-L2.

The evidence supporting this protocol is provided almost exclusively by a single arm, open label phase II multicentre study (KEYNOTE-087) involving a total of 210 patients in three cohorts.r 

Cohort 1 - Progression after ASCT and BV - N = 69
Cohort 2 - Progression after salvage chemo and BV - N = 81
Cohort 3 - Progression after ASCT, but no BV post ASCT (may have had 1st or later line)

Pembrolizumab at a flat dose of 200 mg every three weeks was administered without premedication.  These patients were either relapsed post Autologous stem cell transplant (ASCT), ineligible for ASCT and a minority (approximately 58% of cohort 3 (16.6% overall)) were naive to brentuximab vedotin. 

Across all cohorts, the median number of prior lines of therapy was 4 (range, 1 – 12), with 86.7% of patients having received at least three prior lines.

Between June 2015 and March 2016, 210 patients were treated with pembrolizumab 200 mg every 21 days, planned for up to 24 months treatment.  Data cut-off was in September 2016, giving a median duration of exposure of 8 months (0 – 15).  If patients achieved a PET complete response (CR), pembrolizumab cessation could be considered after a minimum of 6 months treatment, with ≥ 2 doses received after achieving CR.  

The primary end point was Overall Response Rate (ORR) by blinded, centralised assessment.  Secondary endpoints included Investigator assessed ORR, CR rate and Overall Survival (OS), however, the data cut-off was too short to enable this assessment.

Other references related to the utility and rationale for pembrolizumab are noted in the reference section below.  A randomised phase 3 trial comparing brentuximab to pembrolizumab in relapsed/refractory classical Hodgkin lymphoma is underway internationally (ClinicalTrials.gov, NCT02684292).

Source Study & Year Published Supports Use Is the dose and regimen consistent with the protocol? Comments
Phase II trials Chen et al 2017r Yes Yes - 
Phase Ib trials  Armand et al 2016r Yes  N/A  pembrolizumab administered at 10 mg/kg every 2 weeks. 
Guidelines Date published/revised Supports Use Is the dose and regimen consistent with the protocol? Comments
NCCN V.3 2018 Yes N/A - 
BCCA N/A  N/A N/A - 
CCO February 2018 Yes  Yes  - 

Efficacy

After a median follow up of 8 months, the ORR across all cohorts was 69% (CI 62.3 – 75.2).  The CR rate overall was 22.4% (CI 16.9 – 28.6).  Progressive Disease (PD) occurred in 14.3% (CI 9.9 – 19.8).r 

© Journal of Clinical Oncology 2017

Interim analysis at 6 months showed OS 99.5% and Progression Free Survival (PFS) 72.4%.  An ad hoc analysis in December 2016, at 9 months, when 97 patients remained on pembrolizumab, showed OS 97.5% and PFS 63%

Reduction in tumour burden (LEFT) from baseline and Kaplan-Meier estimates of objective response duration (RIGHT) are represented below: A for all patients, B for Cohort 1, C for Cohort 2 and D for Cohort 3.

© Journal of Clinical Oncology 2017

Patients attaining a complete remission (CR) could consider stopping pembrolizumab after a minimum of 6 months of treatment with ≥ 2 doses received after documented CR.r

Updated patient reported outcomes out to 24 weeks have been recently publishedr. There was an improvement in health related quality of life at each time point across all three cohorts (as measured by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 global health status/quality of life score and EuroQoL Five Dimensions Questionnaire).

Two year follow-up of KEYNOTE-087 was presented at the American Society of Haematology (ASH) meeting in 2018r.  Median follow-up was 27.6 months and 5 of the 210 patients were still receiving pembrolizumab therapy.  The ORR was 71.9% (95% CI, 65.3-77.9) and CRR 27.6% (95% CI, 21.7-34.2), response rate by cohort is seen in the table belowr.  Median duration of response was 16.5 months, median PFS was 13.7 months and median OS was not reached.  Overall survival at 2 years was 90.9% and progression free survival was 31.3%.

©Blood 2018

Toxicity

Median number of treatment doses was 13.  The most frequent Grade 3 or 4 treatment-related toxicities were neutropenia (2%), diarrhoea (1%) and dyspnoea (1%).  4.3% of patients discontinued treatment due to adverse events.  At the time of data cut-off, two patients had died, one in each of Cohort 1 and Cohort 2.r 

© Journal of Clinical Oncology 2017

The toxicity data was updated at the two year follow-up of KEYNOTE-087 presented at ASH in 2018r.  Adverse events occurred in 72.9% of patients. Hypothyroidism (14.3%), pyrexia (11.4%), fatigue (11%) and rash (11%) were the most common toxicities.  Grade 3 or 4 treatment related toxicities were seen in 11.9% of patients including neutropenia (2.4%) and diarrhoea (1.4%).  There were no treatment related deaths.  Drug cessation due to a treatment related adverse event occurred in 6.7% of patients.

Primary mediastinal large B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL), however, it is molecularly different from DLBCL and shares many common features with the classical Hodgkin lymphoma (cHL) subtype nodular sclerosing Hodgkin lymphoma (nsHL).

Most patients with newly diagnosed PMBCL are cured from standard frontline therapy such as DA-R-EPOCH with an overall survival (OS) rate of 97%.r For patients with relapsed/refractory PMBCL (rrPMBCL), however, prognosis is poor with limited treatment options. Historically, patients with rrPMBCL have been treated with salvage regimens commonly used for DLBCL such as DHAP, mini-BEAM, transplant, with a 2-year OS of only 15%.r

Pembrolizumab is a humanized anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 and its ligands PD-L1 and PD-L2. Pembrolizumab has shown efficacy in cHL and is approved for the treatment of rrHL.r The rationale for pembrolizumab in the treatment of rrPMBCL, is that PMBCL, like cHL, frequently exhibits 9p24.1 alterations and overexpresses PD-1 ligands.r

In an ongoing multicentre, international phase Ib study of pembrolizumab in patients with rrPMBCL, eligible patients were those with rrPMBCL who had either relapsed after, or were ineligible for autologous stem cell transplant (ASCT) (Keynote-013).r The first 11 of 19 patients received intravenous (IV) pembrolizumab at a dose of 10mg/kg every 2 weeks for the trial’s duration; however, after a study amendment, the subsequent 8 patients received an equivalent regimen with a fixed dose of pembrolizumab 200 mg every 3 weeks. Treatment continued up to 2 years until disease progression or unacceptable toxicity. Treatment response was assessed by PET CT at 6 and 12 weeks, and then every 9 weeks thereafter. Primary endpoints were safety and objective response rate (ORR) by investigator assessment. Secondary endpoints included complete response (CR), duration of response, and time to subsequent lymphoma therapy.

The preliminary efficacy and safety findings in the Keynote-013 trial indicated pembrolizumab has the potential to provide clinical benefit in patients with rrPMBCL and led to the development of the phase II trial (Keynote-170).

The evidence supporting this protocol is provided by an ongoing multicentre, international phase II trial of pembrolizumab (MK-3475) in patients with rrPMBCL or relapsed/refractory Richter syndrome (rrRS) (Keynote-170; NCT02576990). Eligible participants in the rrPMBCL cohort were those who have either failed ASCT or have failed two or more prior lines of therapy and were ineligible for ASCT.r  Patients were treated with pembrolizumab 200mg intravenously (IV) every 3 weeks for a maximum of 35 administrations (approximately 2 years) or until disease progression or unacceptable toxicity. Response was assessed by PET CT every 12 weeks.

The primary endpoint was the ORR assessed by a blinded independent central review using the International Working Group (IWG) response criteria.r Secondary end points included CR, ORR by investigator assessment, duration of response, OS, and safety/tolerability.

Based on the positive results of the interim data from the Keynote-170 trial,r in June 2018, pembrolizumab was granted accelerated approval by the United States Food and Drug Administration for use in rrPMBCL patients who have progressed after two or more lines of prior therapy.

Other references related to the use and rationale for pembrolizumab are noted in the reference section below.  

Source Study & Year Published Supports Use Is the dose and regimen consistent with the protocol? Comments
Phase II trials Zinzani et al 2017r Yes Yes - 
Phase Ib trials  Zinzani et al 2016r Yes  N/A  -
Guidelines Date published/revised Supports Use Is the dose and regimen consistent with the protocol? Comments
NCCN V.2 2018 Yes N/A - 
BCCA February 2019 Yes Yes - 
CCO January 2018 N/A Yes  Approved for Hodgkin lymphoma

Efficacy

At the analysis cut off date (27 May 2016) of the ongoing phase 1b multi-cohort trial assessing the safety and efficacy of pembrolizumab in patients with rrPMBCL (Keynote-013), 19 patients had been enrolled and treated, with 17 patients included in the efficacy analyses (1 patient withdrew prior to receiving any doses and 1 patient did not receive the primary response assessment by time of data cut off).r The median age of participants was 30 years, 72% female, with 61% of participants receiving a median of 3 prior lines of therapy and 33% having had prior ASCT.

The ORR was 41% (7/17). Two patients (11.8%) achieved CR, 5 patients (29.4%) achieved PR and 6 patients (35.3%) had SD with 81% of patients attaining an overall decrease in target lesions.

Similar to the phase I study, interim results from the phase II study (Keynote-170) showed a total of 49 patients with a median age of 33 years, 55% female, who were heavily pre-treated, receiving a median of three prior lines of therapy.r The ORR was also 41% by blinded independent central review, with 14% achieving a CR, 28% achieved a PR, 10% had SD with 28% showing progressive disease and 21% had no assessment (i.e., discontinued or died prior to the 24 week imaging assessment).r Pembrolizumab was well-tolerated with 1 year OS of 62%.r

Toxicity

Overall, the interim results from the phase II study (Keynote-170) showed that pembrolizumab was generally well-tolerated. 35% of patients experienced serious adverse effects and 53% experienced treatment-related adverse events (TRAEs).r

TRAEs ≥ Grade 3 included neutropenia (n=5), increased hepatic enzymes (n=2), Clostridium difficile infection (n=1), tumour flare (n=1), asthenia (n=1), and pneumonia (n=1). One patient experienced grade 4 neutropenia. There were no treatment-related deaths.r

[%id%]
[%title%]
[%abstract%]

Bibliography

Roemer, M. G., R. H. Advani, A. H. Ligon, et al. 2016. "PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome." J Clin Oncol 34(23):2690-2697.

PURPOSE: Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL, chromosome 9p24.1/PD-L1/PD-L2 alterations increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and their further induction through Janus kinase 2-signal transducers and activators of transcription signaling. The unique composition of cHL limits its analysis with high-throughput genomic assays. Therefore, the precise incidence, nature, and prognostic significance of PD-L1/PD-L2 alterations in cHL remain undefined. METHODS: We used a fluorescent in situ hybridization assay to evaluate CD274/PD-L1 and PDCD1LG2/PD-L2 alterations in 108 biopsy specimens from patients with newly diagnosed cHL who were treated with the Stanford V regimen and had long-term follow-up. In each case, the frequency and magnitude of 9p24.1 alterations-polysomy, copy gain, and amplification-were determined, and the expression of PD-L1 and PD-L2 was evaluated by immunohistochemistry. We also assessed the association of 9p24.1 alterations with clinical parameters, which included stage (early stage I/II favorable risk, early stage unfavorable risk, advanced stage [AS] III/IV) and progression-free survival (PFS). RESULTS: Ninety-seven percent of all evaluated cHLs had concordant alterations of the PD-L1 and PD-L2 loci (polysomy, 5% [five of 108]; copy gain, 56% [61 of 108]; amplification, 36% [39 of 108]). There was an association between PD-L1 protein expression and relative genetic alterations in this series. PFS was significantly shorter for patients with 9p24.1 amplification, and the incidence of 9p24.1 amplification was increased in patients with AS cHL. CONCLUSION: PD-L1/PD-L2 alterations are a defining feature of cHL. Amplification of 9p24.1 is more common in patients with AS disease and associated with shorter PFS in this series. Further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted.

Flinders Filters has partnered with eviQ to build reliable, robust search filters to retrieve core high level evidence on topics of significance to eviQ. The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content.

These search filters have been developed to retrieve the most up to date evidence from PubMed, in real time, using specifically designed search filters built to meet our needs.

Searches can be used when a protocol is scheduled for review or at any time you choose. Please click on the Specific, Balanced and Sensitive tabs below to access the Pubmed searches.

Hodgkin lymphoma

Specific Balanced Sensitive
restricted to retrieving randomised control trials and systematic reviews.

is the middle ground between sensitive and specific searches.

retrieves all clinically relevant evidence - generally a broader search on a given topic.

Primary mediastinal large B-cell lymphoma

Specific Balanced Sensitive
restricted to retrieving randomised control trials and systematic reviews.

is the middle ground between sensitive and specific searches.

retrieves all clinically relevant evidence - generally a broader search on a given topic.

Access Flinders Filters, a division of the Flinders Digital Health Research Centre at Flinders University to read more about research solutions to searching problems.

Troubleshooting

Occasionally the searches may not display correctly or take too long to load (and will eventually timeout). This may be caused by Internet Explorer being unable to handle long URL's. You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.

Feedback

If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article(s). 

Version 2

Date Summary of changes
18/11/2020

Protocol updated to align with ID 1993 Management of immune-related adverse events (irAEs) clinical resource which has been electronically reviewed and approved by the eviQ immunotherapy reference committee. The following changes have been made across all immune checkpoint inhibitor protocols:

  • Treatment schedule - additional note added: transient tumour flare and radiation recall.
  • Clinical information- cardiotoxicity, haematological toxicity, musculoskeletal toxicity and ocular toxicity added; rheumatological toxicity removed; immunotherapy clinical information changed to alphabetical order.
  • Side effects- haematological added; rheumatological replaced with musculoskeletal; immunotherapy side effects changed to alphabetical order.

Arthralgia and myalgia non-irAE side effect removed to align with other immune checkpoint inhibitor protocols.

Version number increased to V.2.

Version 1

Date Summary of changes
15/11/2019

New multi-indication protocol developed and presented at the Haematology Reference Committee meeting in September. 
Protocol combined ID 3419 Hodgkin lymphoma pembrolizumab and new indication primary mediastinal large B-cell lymphoma.
Approved and published on eviQ.
Review in 1 year.

As ID 3671 Pembrolizumab replaces the ID 3419 Hodgkin lymphoma pembrolizumab protocol, this History section is  included below for consistency in documentation. 

ID 3419 Hodgkin lymphoma pembrolizumab version 1
Date Summary of changes
21/06/2018

New protocol developed and presented at the May Haematology Reference Committee meeting. Discussion continued over email and protocol approved for publication with a second yearly review period. 

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3671

24 Jan 2021